Faron Pharmaceuticals Oy's latest marketcap:
As of 06/05/2025, Faron Pharmaceuticals Oy's market capitalization has reached $405.56 M. According to our data, Faron Pharmaceuticals Oy is the 15181th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 405.56 M |
| Revenue (ttm) | 0 |
| Net Income (ttm) | -29,675,548.8 |
| Shares Out | 0 |
| EPS (ttm) | -0.34 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/27/2025 |
Faron Pharmaceuticals Oy's yearly market capitalization.
| Date | Market Cap | Change (%) |
|---|---|---|
| 06/05/2025 | €354.23 M | 36.58% |
| 12/31/2024 | €259.36 M | 7.28% |
| 12/29/2023 | €241.77 M | 19.52% |
| 12/30/2022 | €202.28 M | 19.31% |
| 12/31/2021 | €169.54 M | 24.58% |
| 12/31/2020 | €136.09 M |
Company Profile
About Faron Pharmaceuticals Oy
Faron Pharmaceuticals Oy is a clinical-stage drug discovery and development company focused on innovative therapies for severe medical conditions.
Key Product Candidates
- Traumakine: An investigational intravenous interferon beta-1a therapy targeting cytokine release syndrome (CRS), ischemia, and hyperinflammatory conditions.
- Bexmarilimab: A novel anti-Clever-1 humanized antibody designed to reprogram immunosuppressive M2-like macrophages into a pro-inflammatory state, enhancing immune activation.
Therapeutic Focus Areas
The company is advancing bexmarilimab for the treatment of:
- Hematological and solid tumor cancers
- Relapsed/refractory myelodysplastic syndromes (MDS)
- Acute myeloid leukemia (AML)
- Chronic myelomonocytic leukemia (CMML)
Additional Research
Faron Pharmaceuticals is also exploring receptors involved in immune response regulation for applications in organ damage and bone marrow regeneration.
Company Background
Founded in 2003, Faron Pharmaceuticals Oy is headquartered in Turku, Finland.
Frequently Asked Questions
-
What is Faron Pharmaceuticals Oy's (HEL-FARON) current market cap?As of 06/05/2025, Faron Pharmaceuticals Oy (including the parent company, if applicable) has an estimated market capitalization of $405.56 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Faron Pharmaceuticals Oy (HEL-FARON) rank globally by market cap?Faron Pharmaceuticals Oy global market capitalization ranking is approximately 15181 as of 06/05/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.